

CITATION REPORT

List of articles citing

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

DOI: 10.18632/oncotarget.588

Oncotarget, 2012, 3, 709-22.

Source: <https://exaly.com/paper-pdf/54290472/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
499	Genetics of adult glioma. 2012 , 205, 613-21		566
498	Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways. <i>PLoS ONE</i> , 2012 , 7, e52167	3.7	29
497	Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. <i>Brain Pathology</i> , 2013 , 23, 237-43	6	66
496	Molecular neuro-oncology in clinical practice: a new horizon. 2013 , 14, e370-9		149
495	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. 2013 , 126, 443-51		239
494	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. 2013 , 126, 277-89		36
493	A clear picture of renal cell carcinoma. 2013 , 45, 849-50		83
492	Is glioblastoma an epigenetic malignancy?. <i>Cancers</i> , 2013 , 5, 1120-39	6.6	37
491	Neuro-oncology: anaplastic oligodendrogliomas-value of early chemotherapy. 2013 , 9, 7-8		2
490	Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. 2013 , 126, 789-92		11
489	Telomere length and risk of glioma. 2013 , 37, 935-8		26
488	Mutational landscape and significance across 12 major cancer types. 2013 , 502, 333-339		2803
487	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. <i>Neuro-Oncology</i> , 2013 , 15, 1114-26	1	85
486	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. 2013 , 115, 249-59		25
485	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. 2013 , 126, 267-76		256
484	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 2013 , 110, 6021-6		968
483	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. 2013 , 5, 66		17

482	Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. 2013 , 9, 8-10		11
481	The definition of primary and secondary glioblastoma. 2013 , 19, 764-72		640
480	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 2013 , 73, 496-501		99
479	ATRX: the case of a peculiar chromatin remodeler. 2013 , 8, 3-9		62
478	Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. <i>Brain Pathology</i> , 2013 , 23, 210-6	6	64
477	Analysis of CIC-associated CpG island methylation in oligoastrocytoma. 2013 , 39, 831-6		1
476	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. 2013 , 14, 534-42		169
475	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. 2013 , 125, 659-69		201
474	A glioblastoma neurosphere line with alternative lengthening of telomeres. 2013 , 126, 607-8		9
473	Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. 2013 , 72, 298-306		46
472	Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium. 2013 , 34, E9		10
471	Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. 2013 , 118, 1176-80		17
470	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. <i>Neuro-Oncology</i> , 2013 , 15, 682-90	1	19
469	The molecular landscape of diffuse glioma and prospects for biomarker development. 2013 , 7, 573-87		7
468	Molecular insights into brain tumors: ready for translation into novel treatment strategies?. 2013 , 26, 678-80		
467	Next-generation molecular genetics of brain tumours. 2013 , 26, 681-7		14
466	Predictive biomarkers in adult gliomas: the present and the future. <i>Current Opinion in Oncology</i> , 2013 , 25, 689-94	4.2	30
465	Molecular biomarkers in pediatric glial tumors: a needed wind of change. <i>Current Opinion in Oncology</i> , 2013 , 25, 665-73	4.2	11

464	Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. <i>Neuro-Oncology</i> , 2013 , 15, 1041-7	1	36
463	From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. 2013 , 34, E2		37
462	Spinal cord tumours: advances in genetics and their implications for treatment. 2013 , 9, 257-66		45
461	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. 2013 , 14, r106		78
460	MAPping the genomic landscape of low-grade pediatric gliomas. 2013 , 45, 847-9		5
459	A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. <i>PLoS ONE</i> , 2013 , 8, e59773	3.7	34
458	Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing. <i>PLoS ONE</i> , 2013 , 8, e76623	3.7	14
457	Emerging biomarkers in glioblastoma. <i>Cancers</i> , 2013 , 5, 1103-19	6.6	69
456	On the Genesis of Neuroblastoma and Glioma. 2014 , 2014, 1-14		8
455	Telomere maintenance mechanisms in cancer: clinical implications. 2014 , 20, 6361-74		55
454	Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. <i>Frontiers in Oncology</i> , 2014 , 4, 47	5.3	30
453	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014 , 5, 1452-7	3.3	59
452	Quantitative iTRAQ LC-MS/MS Proteomics Reveals Transcription Factor Crosstalk and Regulatory Networks in Hypopharyngeal Squamous Cell Carcinoma. 2014 , 5, 525-36		19
451	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. 2014 , 14, 439-52		63
450	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. 2014 , 128, 853-62		38
449	Molecular characteristics of pediatric high-grade gliomas. 2014 , 3, 433-43		24
448	Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. 2014 , 120, 283-91		6
447	Is the volume of low-grade glioma measurable and is it clinically relevant?. <i>Neuro-Oncology</i> , 2014 , 16, 1027-8	1	4

446	Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". <i>Neuro-Oncology</i> , 2014 , 16, 891-2	1	
445	Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. 2014 , 37, E13		36
444	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. 2014 , 128, 615-27		29
443	Molecular genetics of gliomas. 2014 , 20, 66-72		70
442	Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. 2014 , 38, 1058-70		50
441	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014 , 16, 81-91	1	290
440	Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. 2014 , 74, 4836-44		51
439	Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. <i>Neuro-Oncology</i> , 2014 , 16, 1100-9	1	37
438	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. 2014 , 27, 332-42		32
437	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. <i>Neuro-Oncology</i> , 2014 , 16, 400-8	1	7
436	Using the molecular classification of glioblastoma to inform personalized treatment. 2014 , 232, 165-77		174
435	Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. 2014 , 20, 2898-909		116
434	The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014 , 16, 896-913		1044
433	Pathology of gliomas and developments in molecular testing. 2014 , 26, 377-84		4
432	Gastroenteropancreatic endocrine tumors. 2014 , 386, 101-20		27
431	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. 2014 , 14, 92-107		383
430	Single-cell RNA-seq reveals dynamic, random monoallelic gene expression in mammalian cells. 2014 , 343, 193-6		816
429	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. 2014 , 343, 189-193		912

428	Long noncoding RNA profiles reveal three molecular subtypes in glioma. 2014 , 20, 339-43		55
427	The evolving role of molecular markers in the diagnosis and management of diffuse glioma. 2014 , 20, 5601-11		44
426	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. 2014 , 47-75		1
425	Geroconversion: irreversible step to cellular senescence. 2014 , 13, 3628-35		92
424	Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective. 2014 , 119, 481-90		17
423	Genetic markers in adult high-grade gliomas. 2014 , 24, 235-9		2
422	Section III: molecular diagnostics in neuro-oncology. 2014 , 38, 175-9		6
421	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. 2014 , 111, 2024-32		126
420	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. 2014 , 5, 5006		120
419	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. <i>Neuro-Oncology</i> , 2014 , 16, 173-8	1	22
418	Isocitrate dehydrogenase 1 and 2 mutations in gliomas. 2014 , 92, 1611-20		14
417	Epidemiologic and molecular prognostic review of glioblastoma. 2014 , 23, 1985-96		591
416	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014 , 16, 1541-6	1	12
415	Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. 2014 , 14, 506		17
414	Molecular neuro-oncology and the challenge of the blood-brain barrier. 2014 , 41, 438-445		11
413	[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors]. 2014 , 85, 965-75		1
412	Telomerase promoter mutations in cancer: an emerging molecular biomarker?. 2014 , 465, 119-33		80
411	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. 2014 , 32, 783-90		280

410	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. 2014 , 128, 551-9		200
409	Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling. 2014 , 119, 243-51		2
408	Histone variants: emerging players in cancer biology. 2014 , 71, 379-404		117
407	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. 2014 , 2, 831-840		
406	Genetics and epigenetics of gliomas. 2014 , 144, w14018		6
405	Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 665-72	7:3	7
404	Pathology and genetics of diffuse gliomas in adults. 2015 , 55, 28-37		10
403	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. 2015 , 3, 88		27
402	CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. 2015 , 74, 442-52		91
401	Targeted genomic analysis of Müllerian adenosarcoma. 2015 , 235, 37-49		61
400	ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas. 2015 , 54, 725-33		33
399	Clinical management of grade III oligodendroglioma. 2015 , 7, 213-23		15
398	Application of Volumetric Analysis to Glioblastomas: a Correlation Study on the Status of the Isocitrate Dehydrogenase Mutation. 2015 , 19, 218		
397	Heavy metals and epigenetic alterations in brain tumors. 2014 , 15, 457-63		39
396	Modern brain tumor imaging. 2015 , 3, 8-23		117
395	New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. 2015 , 12, 201-13		70
394	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015 , 6, 20885-901	3:3	35
393	The evolving molecular genetics of low-grade glioma. 2015 , 22, 94-101		59

392	Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. 2015 , 22, 1219-26	35
391	Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. 2015 , 46, 1323-30	23
390	Oligodendroglioma: pathology, molecular mechanisms and markers. 2015 , 129, 809-27	128
389	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. 2015 , 129, 789-808	39
388	Biomarker-driven diagnosis of diffuse gliomas. 2015 , 45, 87-96	57
387	Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells. 2015 , 35, 2818-30	32
386	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. 2015 , 41, 694-720	72
385	Emerging roles of ATRX in cancer. 2015 , 7, 1365-78	41
384	Oligodendrogliomas: a short history of clinical developments. 2015 , 4, 281-5	4
383	Quelle est la place de la biologie moléculaire en neuropathologie tumorale en 2015?. 2015 , 6, 175-180	
382	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?. 2015 , 129, 151-3	68
381	TERT promoter mutation designates biologically aggressive primary glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 5-6	1 4
380	Low-Grade Gliomas. 2015 , 45-66	
379	Oligodendroglial Tumors. 2015 , 105-120	
378	Practical molecular pathologic diagnosis of infiltrating gliomas. 2015 , 8, 49-61	1
377	Genomic discoveries in adult astrocytoma. 2015 , 30, 17-24	8
376	Survival and low-grade glioma: the emergence of genetic information. 2015 , 38, E6	212
375	p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. 2015 , 46, 231-8	20

374	Clinical impact of molecular biomarkers in gliomas. 2015 , 22, 437-44		49
373	Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. 2015 , 6, 6140		115
372	Tumor-specific mutations in low-frequency genes affect their functional properties. 2015 , 122, 461-70		10
371	Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. 2015 , 121, 141-50		75
370	The future of high-grade glioma: Where we are and where are we going. <i>Surgical Neurology International</i> , 2015 , 6, S9-S44	1	22
369	Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. 2015 , 15, 603-6		9
368	Genetic Classification of Gliomas: Refining Histopathology. 2015 , 28, 9-11		34
367	Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery. <i>Neuro-Oncology</i> , 2015 , 17, 1560-7	1	40
366	Applicable advances in the molecular pathology of glioblastoma. 2015 , 32, 153-62		11
365	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 2015 , 372, 2481-98		1828
364	Molecular profiling of gliomas: potential therapeutic implications. 2015 , 15, 955-62		15
363	Molecular heterogeneity in glioblastoma: potential clinical implications. <i>Frontiers in Oncology</i> , 2015 , 5, 55	5.3	125
362	Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. 2015 , 208, 91-5		26
361	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. 2015 , 129, 585-96		211
360	The Emerging Molecular Foundations of Pediatric Brain Tumors. 2015 , 30, 1838-50		15
359	Molecular and Genomic Alterations in Glioblastoma Multiforme. 2015 , 185, 1820-33		101
358	Anaplastic glioma: current treatment and management. 2015 , 15, 601-20		19
357	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. 2015 , 129, 679-93		208

356	Glioblastoma: pathology, molecular mechanisms and markers. 2015 , 129, 829-48	360
355	Chemotherapy in glioma. 2015 , 4, 179-92	36
354	Next Generation Sequencing in Cancer Research, Volume 2. 2015 ,	4
353	Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. 2015 , 22, 50-8	62
352	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. 2015 , 123, 373-83	11
351	Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade. 2015 , 74, 241-9	28
350	Mutational landscape and clonal architecture in grade II and III gliomas. 2015 , 47, 458-68	543
349	Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification. 2015 , 25, 155-63	41
348	The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. 2015 , 125, 531-49	29
347	CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. 2015 , 78, 355-74	57
346	Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development. 2015 , 11, 2587-601	13
345	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. 2015 , 28, 307-317	176
344	Spatiotemporal Evolution of the Primary Glioblastoma Genome. 2015 , 28, 318-28	180
343	Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation. 2015 , 36, 2023-9	29
342	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. 2015 , 4, 287-94	34
341	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. 2015 , 139, 1087-93	12
340	Molecular Pathology of Nervous System Tumors. 2015 ,	1
339	Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy. 2015 , 22, 14-22	10

338	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. 2015 , 129, 133-46		313
337	Glioma biology and molecular markers. 2015 , 163, 15-30		114
336	Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. <i>Brain Pathology</i> , 2015 , 25, 418-28	6	6
335	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. 2015 , 121, 479-87		12
334	Oligoastrocytoma: A Vanishing Tumor Entity. 2016 ,		
333	Molecular Advances in Glioblastoma Neuropathology. 2016 ,		3
332	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , 2016 , 7, 16384-95	3.3	40
331	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. <i>Oncotarget</i> , 2016 , 7, 64615-64630	3.3	17
330	ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	78
329	Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	7
328	Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. <i>PLoS ONE</i> , 2016 , 11, e0168728	3.7	4
327	Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. 2016 , 31, 1208-14		40
326	Evolving Molecular Genetics of Glioblastoma. 2016 , 129, 464-71		32
325	New perspectives in glioblastoma antiangiogenic therapy. 2016 , 20, 109-18		18
324	Neuropathology of gliomas. 146-168		
323	Role of microRNAs Located on Chromosome Arm 10q in Malignant Gliomas. <i>Brain Pathology</i> , 2016 , 26, 344-58	6	16
322	Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. 2016 , 375, 2381-2389		3
321	Genetics of glioma. 1-23		1

320	Further understanding of the pathology of glioma: implications for the clinic. 2016 , 16, 1055-65	15
319	Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. 2016 , 21, 214-9	31
318	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. 2016 , 29, 737-750	31
317	ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. 2016 , 3, e1167158	31
316	CGCG clinical practice guidelines for the management of adult diffuse gliomas. 2016 , 375, 263-273	253
315	Big data visualization identifies the multidimensional molecular landscape of human gliomas. 2016 , 113, 5394-9	35
314	Molecular classification of gliomas. 2016 , 134, 97-120	65
313	Actionable molecular biomarkers in primary brain tumors. 2016 , 2, 338-349	29
312	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. 2016 , 4, 79	137
311	Low-grade and anaplastic oligodendroglioma. 2016 , 134, 361-80	19
310	ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors. 2016 , 130, 63-68	2
309	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. 2016 , 9, 379-90	3
308	Genomic Landscape of Brain Tumors. 2016 , 653-663	
307	Recent advances and future of immunotherapy for glioblastoma. 2016 , 16, 1245-64	50
306	ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. 2016 , 8, 328ra28	146
305	TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. 2016 , 6, 29714	10
304	The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. 2016 , 139, 414-23	41
303	Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment. 2016 , 35, 12	14

302	ATRX immunostaining predicts IDH and H3F3A status in gliomas. 2016 , 4, 60		76
301	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. 2016 , 16, 15		22
300	Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the Integrated Diagnosis approach. 2016 , 69, 686-94		17
299	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. 2016 , 11, 497-521		27
298	Genotyping low-grade gliomas among Hispanics. 2016 , 3, 164-172		2
297	Special Techniques. 2016 , 11-44		
296	Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. 2016 , 33, 107-16		33
295	Biomarkers in Neoplastic Neuropathology. 2016 ,		
294	Epidemiology. 2016 , 134, 3-18		13
293	Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1099-108	1	71
292	Targeted next-generation sequencing panel (GliSeq) provides comprehensive genetic profiling of central nervous system tumors. <i>Neuro-Oncology</i> , 2016 , 18, 379-87	1	75
291	An epigenetic gateway to brain tumor cell identity. 2016 , 19, 10-9		65
290	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. 2016 , 75, 4-18		59
289	Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. 2016 , 91-108		22
288	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016 , 18, 388-400	1	102
287	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 16-26	1	166
286	ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. <i>Brain Pathology</i> , 2017 , 27, 138-145	6	11
285	The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. 2017 , 132, 1-11		32

284	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. 2017 , 31, 181-193	350
283	Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted). 2017 , 251-263	
282	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. 2017 , 77, 1709-1718	117
281	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. 2017 , 17, 19	66
280	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. 2017 , 133, 1001-1016	185
279	ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. 2017 , 34, 20-27	3
278	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. 2017 , 141, 355-365	2
277	Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?. 2017 , 76, 342-346	15
276	Recent advances in subtyping tumors of the central nervous system using molecular data. 2017 , 17, 83-94	9
275	Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. 2017 , 134, 65-74	32
274	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , 2017 , 19, 614-624	1 79
273	Central nervous system gliomas. 2017 , 113, 213-234	84
272	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. 2017 , 134, 541-549	68
271	Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. 2017 , 1865, 875-890	27
270	Personalized Medicine Through Advanced Genomics. 2017 , 31-48	1
269	A double-edged sword: The world according to Capicua in cancer. 2017 , 108, 2319-2325	16
268	Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. <i>Cancer</i> , 2017 , 123, 4535-4546	6.4 71
267	Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. 2017 , 7, 13038	4

266	Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. 2017 , 77, 6097-6108		27
265	Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region. 2017 , 41, 1238-1246		13
264	CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS. 2017 , 28, 343-351		5
263	T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. 2017 , 23, 6078-6085		157
262	Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis. 2017 , 135, 381-390		14
261	Characterization of gliomas: from morphology to molecules. 2017 , 471, 257-269		57
260	Pediatric High Grade Glioma. 2017 , 241-266		1
259	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. <i>Neuro-Oncology</i> , 2017 , 19, 1640-1650	1	36
258	Advances in Biology and Treatment of Glioblastoma. 2017 ,		
257	Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. 2017 , 131, 403-412		15
256	Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. 2017 , 131, 213-222		17
255	Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma. 2017 , 84, 99-107		12
254	Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors. 2018 , 15, 1459-1468		2
253	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. 2017 , 64, 134-138		20
252	CIC (capicua transcriptional repressor). 2017 ,		
251	Epigenetic dysregulation in brain tumors and neurodevelopment. 2017 , 261-276		
250	MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. 2017 , 2017, 9157370		14
249	Comparative analysis of primary relapse/refractory DLBCL identifies shifts in mutation spectrum. <i>Oncotarget</i> , 2017 , 8, 99237-99244	3-3	14

248	Molecular Testing of Brain Tumor. 2017 , 51, 205-223	44
247	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. 2018 , 25, 143-171	23
246	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. 2018 , 139, 349-357	15
245	Sequencing the next generation of glioblastomas. 2018 , 55, 264-282	14
244	Reconstructing the molecular life history of gliomas. 2018 , 135, 649-670	44
243	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. 2018 , 188, 168-175	27
242	Central Nervous System and Peripheral Nerves. 2018 , 571-607	1
241	Pathology and Genetics of Gliomas. 2018 , 31, 1-37	12
240	Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. 2018 , 28, 2960-2968	51
239	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018 , 20, 873-884	1 63
238	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. 2018 , 210, 621-628	52
237	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. 2018 , 28, 4350-4361	42
236	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. 2018 , 9, 1057	39
235	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. 2018 , 38, 32-40	15
234	What's New in Grade II and Grade III Gliomas?. 2018 , 38, 41-49	0
233	New Directions in the Treatment of Glioblastoma. 2018 , 38, 50-61	23
232	Practical Implications of the Updated WHO Classification of Brain Tumors. 2018 , 38, 11-18	3
231	Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis. 2018 , 11, 70-75	0

230 Pheochromocytomas and Paragangliomas: Genetics and Pathophysiology. **2018**, 173-196

229 Biomarkers and therapeutic advances in glioblastoma multiforme. **2018**, 14, 40-51

78

228 Astrocytic and Oligodendroglial Tumors. **2018**, 91-123

0

227 Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. **2018**, 136, 223-231

2

226 A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. **2018**, 71, 323-329

8

225 Significance of TERT and ATRX mutations in glioma. **2019**, 17, 95-102

16

224 Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. **2018**, 34, 430-442

4

223 Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. **2018**, 10, 7558

7

222 The 2016 World Health Organization classification of tumours of the central nervous system. **2018**, 47, e187-e200

37

221 Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas. *PLoS ONE*, **2018**, 13, e0203639

3.7 13

220 ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. *PLoS ONE*, **2018**, 13, e0204159

3.7 23

219 Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. *International Journal of Molecular Sciences*, **2018**, 19,

6.3 15

218 TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. **2018**, 6, 106

12

217 Combination therapy to checkmate Glioblastoma: clinical challenges and advances. **2018**, 7, 33

91

216 Study of Histomolecular Classification of Glioma-Integrating Histology and Molecular Analysis in the Diagnosis of Brain Tumors. *Indian Journal of Neurosurgery*, **2018**, 07, 129-134

0.1

215 Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. **2018**, 39, 1814-1820

33

214 Using genomics to guide treatment for glioblastoma. **2018**, 19, 1217-1229

9

213 The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. **2018**, 9, 2087

78

212	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. 2018 , 139, 307-322		1
211	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 642-645	7.3	2
210	Conflicting IDH1/IDH2, ATRX, and 1p/19q results in diffuse gliomas: a commentary. 2018 , 82, 297-298		
209	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. 2018 , 116, 495-504		10
208	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. 2018 , 36, 421-437		7
207	Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma. 2018 , 9, 3142		31
206	Mutant ATRX: uncovering a new therapeutic target for glioma. 2018 , 22, 599-613		42
205	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. 2019 , 11,		46
204	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. 2019 ,		
203	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. <i>Neuro-Oncology</i> , 2019 , 21, v1-v100	1	944
202	ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. 2019 , 38, e96659		30
201	Epigenetic Reprogramming for Targeting -Mutant Malignant Gliomas. <i>Cancers</i> , 2019 , 11,	6.6	10
200	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	19
199	Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases. <i>Frontiers in Oncology</i> , 2019 , 9, 828	5.3	5
198	Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects. 2019 , 1, vdz013		2
197	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019 , 21, 669-677	1	19
196	ATRX tames repetitive DNA within heterochromatin to promote normal brain development and regulate oncogenesis. 2019 , 235-257		
195	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. 2019 , 138, 331-334		15

194 Neuro-oncology. **2019**, 391-457

193 DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. *DNA Repair*, **2019**, 78, 128-141 43 47

192 ATRX immunohistochemistry can help refine ~~Q~~ot elsewhere classified ~~Q~~ategorisation for grade II/III gliomas. **2019**, 33, 536-540 1

191 Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. **2019**, 32, 1236-1243 24

190 Tumor Genetics and Their Outcomes on Surgery and Survival. **2019**, 191-203

189 Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. **2019**, 60, 2635-2645 2

188 A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma. **2019**, 9, 2615 30

187 Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency. **2019**, 132, 14

186 Biomarkers in tumors of the central nervous system - a review. **2019**, 127, 265-287 8

185 Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. **2019**, 14, 16 6

184 G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. **2019**, 10, 943 79

183 The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. **2019**, 53, 483-503 14

182 shRNA-mediated PPAR γ knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth. **2019**, 247, 422-434 5

181 Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. **2019**, 25, 1261-1271 31

180 The Germline Variants rs61757955 and rs34988193 Are Predictive of Survival in Lower Grade Glioma Patients. **2019**, 17, 1075-1086 6

179 Helicase Dysfunctions in Human Diseases. **2019**, 191-210 0

178 Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis. **2019**, 26, 379-387 13

177 Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of -Mutant Cancers to WEE1 Inhibition. **2020**, 80, 510-523 23

176	Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. 2020 , 81, 64-70		22
175	Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. 2020 , 22, 963-977		18
174	Pathology, Biomarkers, and Molecular Diagnostics. 2020 , 225-253.e8		3
173	Glioma Imaging. 2020 ,		2
172	ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity. 2020 , 18, e3000594		17
171	Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status. 2020 , 62, 319-326		14
170	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. 2020 , 27, 206-219		4
169	Novel Treatment Strategies for Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	14
168	Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1707	5.3	2
167	The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. 2020 , 150, 143-164		1
166	High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. 2020 , 40, 599-605		1
165	Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. 2020 , 2, vdaa042		7
164	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. 2020 , 38, 3407-3417		39
163	Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas. 2020 , 30, 6464-6474		1
162	The Emerging Role of Extracellular Vesicles in the Glioma Microenvironment: Biogenesis and Clinical Relevance. <i>Cancers</i> , 2020 , 12,	6.6	9
161	The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. 2020 , 71, 127-137		2
160	-wildtype secondary glioblastoma arising in -mutant diffuse astrocytoma: a case report. 2020 , 1-4		
159	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. <i>Neuro-Oncology</i> , 2020 , 22, iv1-iv96	1	429

158	Epigenomic Reprogramming as a Driver of Malignant Glioma. 2020 , 38, 647-660		25
157	miRNA-182 regulated MTSS1 inhibits proliferation and invasion in Glioma Cells. 2020 , 11, 5840-5851		2
156	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020 , 12,	6.6	20
155	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. 2020 , 8,		20
154	IDH mutations in older patients with diffuse astrocytic gliomas. 2020 , 49, 151653		2
153	The biological and clinical basis for early referral of low grade glioma patients to a surgical neuro-oncologist. 2020 , 78, 20-29		2
152	IDH-Mutant Gliomas. 2020 ,		3
151	Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. 2020 , 148, 473-480		0
150	Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. 2020 , 11, 1402		50
149	Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. 2020 , 19, 407-417		5
148	Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening. <i>Cancers</i> , 2020 , 12,	6.6	1
147	Radiomics Features Predict CIC Mutation Status in Lower Grade Glioma. <i>Frontiers in Oncology</i> , 2020 , 10, 937	5.3	7
146	Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. <i>Cancers</i> , 2020 , 12,	6.6	22
145	Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors. 2020 , 60, 147-155		3
144	Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features. 2020 , 10, 3711		21
143	Retrospective and Randomized Analysis of Influence and Correlation of Clinical and Molecular Prognostic Factors in a Mono-Operative Series of 122 Patients with Glioblastoma Treated with STR or GTR. 2020 , 10,		8
142	MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas. 2020 , 30, 3035-3045		3
141	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8

140	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. 2020 , 147, 1-14	7
139	Probing the Protein-Protein Interaction Between the ATRX Domain and the Histone H3 Tail. 2020 , 25,	
138	1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma. 2020 , 46, 151519	3
137	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. 2021 , 106, 1183-1194	16
136	Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. 2021 , 26, 173-177	12
135	Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates. 2021 , 31, 749-763	3
134	A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. 2021 , 20, 83-98	4
133	Plasma amino acids indicate glioblastoma with ATRX loss. 2021 , 53, 119-132	1
132	Molecular Stratification of Adult and Pediatric High Grade Gliomas. 2021 , 123-151	
131	Identification of CRYAB+ KCNN3+ SOX9+ astro-like and EGFR+ PDGFRA+ OLIG1+ oligo-like tumoral cells in diffuse low-grade gliomas and implication of Notch1 signalling in their genesis.	
130	Mutation-based clustering and classification analysis reveals distinctive age groups and age-related biomarkers for glioma. 2021 , 21, 77	5
129	Identifying modules of cooperating cancer drivers. 2021 , 17, e9810	2
128	Chromoanagenesis landscape in 10,000 TCGA patients.	
127	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. 2021 , 15, 551-561	9
126	Identification of CRYAB KCNN3 SOX9 Astrocyte-Like and EGFR PDGFRA OLIG1 Oligodendrocyte-Like Tumoral Cells in Diffuse IDH1-Mutant Gliomas and Implication of NOTCH1 Signalling in Their Genesis. <i>Cancers</i> , 2021 , 13,	6.6 2
125	The Multiple Facets of ATRX Protein. <i>Cancers</i> , 2021 , 13,	6.6 1
124	ALT Positivity in Human Cancers: Prevalence and Clinical Insights. <i>Cancers</i> , 2021 , 13,	6.6 7
123	Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. 2021 , 9, 95	2

122	Mouse Models of Experimental Glioblastoma. 15-46		0
121	Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas. 2021 , 12, 2584		3
120	SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. 2021 , 34, 1810-1819		1
119	Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. 2021 , 41, 2499-2510		0
118	The implications of IDH mutations for cancer development and therapy. 2021 , 18, 645-661		21
117	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
116	A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database. <i>Cancers</i> , 2021 , 13,	6.6	6
115	Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis. 2021 , 3, vdab109		1
114	Chromoanagenesis Landscape in 10,000 TCGA Patients. <i>Cancers</i> , 2021 , 13,	6.6	0
113	Prognostic and Predictive Biomarkers in Gliomas. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
112	Activity of Wnt/PCP Regulation Pathway Classifies Patients of Low-Grade Glioma Into Molecularly Distinct Subgroups With Prognostic Difference. <i>Frontiers in Oncology</i> , 2021 , 11, 726034	5.3	0
111	Polycomb repressive complex 2 in the driver@seat of childhood and young adult brain tumours. 2021 , 31, 814-828		5
110	Glioblastoma with primitive neuronal component: An immunohistochemical study and review of literature. 2021 , 93, 130-136		0
109	Genetic Architectures and Cell-of-Origin in Glioblastoma. <i>Frontiers in Oncology</i> , 2020 , 10, 615400	5.3	4
108	MRI Features May Predict Molecular Features of Glioblastoma in Wild-Type Lower-Grade Gliomas. 2021 , 42, 448-456		13
107	Adult High-Grade (Diffuse) Glioma. 2015 , 77-93		2
106	MRS for D-2HG Detection in IDH-Mutant Glioma. 2020 , 173-189		1
105	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. 2017 , 73-100		1

104	Dissecting telomere maintenance mechanisms in pediatric glioblastoma.		4
103	Reconstructing the Molecular Life History of Gliomas.		2
102	CIC is a critical regulator of neuronal differentiation. 2020 , 5,		8
101	Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. 2013 , 123, 2049-63		74
100	A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. 2020 , 10, 42		6
99	CNS Tumors in Adolescents and Young Adults: The Need for a Holistic Specialized Approach. <i>JCO Oncology Practice</i> , 2020 , 16, 155-162	2.3	6
98	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. <i>PLoS Genetics</i> , 2017 , 13, e1006622	6	36
97	Molecular subtypes of glioblastoma are relevant to lower grade glioma. <i>PLoS ONE</i> , 2014 , 9, e91216	3.7	67
96	PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. <i>PLoS ONE</i> , 2015 , 10, e0142750	3.7	9
95	Glioblastoma Genomics: A Very Complicated Story. 3-25		8
94	Molecular Genetics of Secondary Glioblastoma. 27-42		8
93	mutation-specific radiomic signature in lower-grade gliomas. <i>Aging</i> , 2019 , 11, 673-696	5.6	26
92	GBM-associated mutations and altered protein expression are more common in young patients. <i>Oncotarget</i> , 2016 , 7, 69466-69478	3.3	19
91	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017 , 8, 35523-35536	3.3	35
90	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014 , 5, 1515-25	3.3	187
89	PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma. <i>Oncotarget</i> , 2017 , 8, 46348-46362	3.3	28
88	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. <i>Oncotarget</i> , 2014 , 5, 2551-61	3.3	55
87	Remote intracranial recurrence of mutant gliomas is associated with mutations and an 8q gain. <i>Oncotarget</i> , 2017 , 8, 84729-84742	3.3	7

86	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. <i>Oncotarget</i> , 2014 , 5, 7960-79	3.3	28
85	Multidimensional analysis of gene expression reveals TGFB11-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014 , 5, 12593-606	3.3	31
84	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. <i>Oncotarget</i> , 2019 , 10, 3641-3653	3.3	1
83	TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. <i>Oncotarget</i> , 2015 , 6, 10617-33	3.3	60
82	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015 , 6, 7318-24	3.3	33
81	Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. <i>Oncotarget</i> , 2015 , 6, 15871-81	3.3	9
80	Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. <i>Oncotarget</i> , 2015 , 6, 18105-15	3.3	41
79	Cut from the same cloth Shared microsatellite variants among cancers link to ectodermal tissues-neural tube and crest cells. <i>Oncotarget</i> , 2015 , 6, 22038-47	3.3	5
78	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. <i>Oncotarget</i> , 2015 , 6, 30295-305	3.3	86
77	Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. <i>Oncotarget</i> , 2012 , 3, 1194-203	3.3	200
76	Exomic sequencing of four rare central nervous system tumor types. <i>Oncotarget</i> , 2013 , 4, 572-83	3.3	57
75	Molecular Biomarkers of Brain and Spinal Cord Astrocytomas. <i>Acta Naturae</i> , 2019 , 11, 17-27	2.1	7
74	Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. <i>Annals of Translational Medicine</i> , 2015 , 3, 95	3.2	61
73	Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas. <i>Neurology India</i> , 2020 , 68, 832-837	0.7	3
72	, , and V600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. <i>Surgical Neurology International</i> , 2018 , 9, 29	1	6
71	Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. 2014 , 33, 108-11		14
70	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1537-1570	7.3	83
69	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <i>Cancer</i> , 2021 ,	6.4	11

68	How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 114-6	7.1	
67	CIC Mutation as Signature Alteration in Oligodendroglioma. 2015 , 423-440		
66	Translating Molecular Biomarkers of Gliomas to Clinical Practice. 2016 , 33-53		
65	Brain Tumours. 1-11		
64	Molecular Carcinogenesis of Glial Brain Tumors. 2017 , 115-136		
63	Molecular Testing for Glioblastoma. 2017 , 339-347		
62	Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas.		
61	High-Grade Gliomas. 2018 , 83-102		
60	Low-Grade Glioma. 2018 , 65-82		
59	Inactivation of hepatic ATRX in Foxg1cre mice prevents reversal of aging-like phenotypes by thyroxine. <i>Aging</i> , 2018 , 10, 1223-1238	5.6	
58	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.		
57	The Germline Variants rs61757955 and rs34988193 are Predictive of Survival in Low Grade Glioma Patients.		o
56	Molecular Diagnosis in WHO Classification of Tumours of the Central Nervous System 2016 : A Domestic Survey and Perspectives. <i>Japanese Journal of Neurosurgery</i> , 2019 , 28, 674-685		o
55	CIC is a Critical Regulator of Neuronal Differentiation.		
54	Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1.		
53	A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targets.		o
52	Clinical Relevance of Alternative Lengthening of Telomeres in Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 485-497	3	
51	Biomarkers for pediatric cancer detection: latest advances and future perspectives. <i>Biomarkers in Medicine</i> , 2020 , 14, 391-400	2.3	1

50	Central Nervous System Tumor Classification: An Update on the Integration of Tumor Genetics. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 1-21	3.1	
49	Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population. <i>PLoS ONE</i> , 2020 , 15, e0242793	3.7	
48	A review of gliomas-related proteins. Characteristics of potential biomarkers. <i>American Journal of Cancer Research</i> , 2021 , 11, 3425-3444	4.4	1
47	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.. <i>Cell Reports</i> , 2022 , 38, 110216	10.6	2
46	Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.. <i>Neuro-Oncology</i> , 2022 ,	1	0
45	Multiple Faces of the Glioblastoma Microenvironment.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
44	Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.. <i>Brain Pathology</i> , 2022 , e13062	6	2
43	ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors.. <i>Cancers</i> , 2022 , 14,	6.6	0
42	Applications of chemical exchange saturation transfer MRI in identifying genetic markers in gliomas.. <i>NMR in Biomedicine</i> , 2022 , e4731	4.4	0
41	Clinical, Morphological, and Molecular Study of Diffuse WHO Grade II and III Astrocytomas: A Retrospective Analysis from a Single Tertiary Care Institute. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021 , 42, 569-576	0.2	
40	Tumors of the Glia: Recent Advances. 2022 , 353-386		
39	Introduction to Pathologic Techniques. 23-39		
38	Data_Sheet_1.XLS. 2020 ,		
37	Data_Sheet_2.docx. 2020 ,		
36	Data_Sheet_1.docx. 2019 ,		
35	Data_Sheet_2.docx. 2019 ,		
34	Data_Sheet_3.pdf. 2019 ,		
33	Data_Sheet_4.zip. 2019 ,		

32 Data_Sheet_1.DOCX. **2020**,

31 Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication.. *Frontiers in Oncology*, **2022**, 12, 839302 5.3 0

30 DNMT inhibitor (decitabine) attenuates tuberculosis-induced spine injury by modulating the expression of microRNA-155 and matrix metalloproteinase-13 via suppressing the hypermethylation of IDH mutant. *Biochemical and Biophysical Research Communications*, **2022**, 3.4

29 New twists to the ALternative endings at telomeres.. *DNA Repair*, **2022**, 115, 103342 4.3 1

28 Epidemiology of Glioblastoma MultiformeLiterature Review. *Cancers*, **2022**, 14, 2412 6.6 9

27 Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.. *World Journal of Surgical Oncology*, **2022**, 20, 146 3.4 1

26 Loss of the chromatin remodeler, ATRX, promotes aggressive features of osteosarcoma with increased NF- κ B signaling and integrin receptor binding.

25 Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. *Journal of Cancer Research and Therapeutics*, **2022**, 1.2

24 Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors. *Indian Journal of Neurosurgery*, 0.1

23 CIC-DUX4 sarcomas. *Current Opinion in Oncology*, Publish Ahead of Print, 4.2 0

22 Glycosylation modification identifies novel molecular phenotypes and prognostic stratifications of glioma. *Gene*, **2022**, 836, 146677 3.8

21 Tumors of the nervous system. **2023**, 203-228

20 Current and Future Frontiers of Molecularly Defined Oligodendrogliomas. *Frontiers in Oncology*, 12, 5.3

19 Chromosomal instability in adult-type diffuse gliomas. **2022**, 10, 0

18 Cancer-associated SMARCA1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells. 0

17 ATRX status in patients with gliomas: Radiomics analysis. **2022**, 101, e30189 1

16 Loss of ATRX promotes aggressive features of osteosarcoma with increased NF- κ B signaling and integrin binding. **2022**, 7, 0

15 Small round cell sarcomas. **2022**, 8, 0

14	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.	2
13	Machine learning-based identification of SOX10 as an immune regulator of macrophage in gliomas. 13,	o
12	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). 2022 , 25,	o
11	Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.	o
10	Integrated analysis of genome-wide DNA methylation and cancer-associated fibroblasts identified prognostic biomarkers and immune checkpoint blockade in lower grade gliomas. 12,	o
9	NCCN Guidelines [®] Insights: Central Nervous System Cancers, Version 2.2022. 2023 , 21, 12-20	o
8	Chromatin mutations in pediatric high grade gliomas. 12,	o
7	Cancer-associated SMARCA1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.	o
6	The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. 2023 , 15, 2228	o
5	Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.	o
4	Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. 2023 , 21, 120-129	o
3	Genomic Profiling of lower-grade gliomas subtype with distinct molecular and clinicopathologic characteristics via altered DNA-damage repair features.	o
2	R-Loops at Chromosome Ends: From Formation, Regulation, and Cellular Consequence. 2023 , 15, 2178	o
1	Expression Profiling of IDH, p53, ATRX, and KI-67 Immunostains as Potential Grid for Molecular Subtyping of Adult Diffuse Gliomas from Pakistan.	o